News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1
5,98
EUR
+0,84 % +0,05
8. April 2026, 23:00 Uhr,
Lang & Schwarz
Kommentare 587
x
x3Tim,
18. Feb 15:37 Uhr
0
https://www.businesswire.com/news/home/20260218759994/en/ImmunityBio-Receives-Authorization-from-the-European-Commission-for-ANKTIVA-with-BCG-for-Non-Muscle-Invasive-Bladder-Cancer-Carcinoma-in-Situ-Expanding-Global-Access-to-33-Countries
Lirumlarum1,
17. Feb 13:37 Uhr
0
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-productive-regulatory-engagement-saudi-food?field_nir_news_date_value[min]=
captainpump97,
2. Feb 13:06 Uhr
1
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell?field_nir_news_date_value[min]=
captainpump97,
27. Jan 21:28 Uhr
0
https://youtu.be/kdKE1HcNMS0
O
OriKo,
27. Jan 13:55 Uhr
0
https://de.investing.com/news/analyst-ratings/btig-hebt-kursziel-fur-immunitybio-nach-verbesserten-aussichten-auf-9-usdollar-ann-93CH-3311302
O
OriKo,
27. Jan 13:53 Uhr
0
https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-immunitybio-stock-price-target-to-10-on-anktiva-progress-93CH-4464972
Lirumlarum1,
23. Jan 13:03 Uhr
0
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-median-overall-survival-not-yet-reached-and?field_nir_news_date_value[min]=
Lirumlarum1,
20. Jan 10:03 Uhr
0
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-advances-regulatory-discussions-fda-potential?field_nir_news_date_value[min]=
Lirumlarum1,
16. Jan 13:05 Uhr
0
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-advances-first-line-bcg-naive-nmibc-program?field_nir_news_date_value[min]=
Lirumlarum1,
16. Jan 13:04 Uhr
0
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-durable-complete-response-15-months?field_nir_news_date_value[min]=
Mehr zu diesem Wert
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Trading- und Aktien-Chat | ||
| 2 | NVIDIA Hauptdiskussion | +2,23 % | |
| 3 | ATOS Hauptdiskussion | +2,86 % | |
| 4 | DeFi Technologies: Eine Perle? | +2,63 % | |
| 5 | BYD Hauptdiskussion | +2,68 % | |
| 6 | ROHÖL WTI Hauptdiskussion | -12,46 % | |
| 7 | DAX Hauptdiskussion | +3,64 % | |
| 8 | SERVICENOW Hauptdiskussion | -3,02 % | |
| 9 | Battalion | -11,51 % | |
| 10 | SOUTH32 LTD Hauptdiskussion | +7,62 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | NVIDIA Hauptdiskussion | +2,22 % | |
| 2 | ATOS Hauptdiskussion | +2,86 % | |
| 3 | DeFi Technologies: Eine Perle? | +2,35 % | |
| 4 | BYD Hauptdiskussion | +2,68 % | |
| 5 | XIAOMI CORP. CL.B Hauptdiskussion | +4,95 % | |
| 6 | Battalion | -11,96 % | |
| 7 | SOUTH32 LTD Hauptdiskussion | +7,62 % | |
| 8 | Krown.Network | +10,50 % | |
| 9 | Tungsten West Hauptdiskussion | +18,57 % | |
| 10 | Allgemeines zu Intellistake Technologies | -11,17 % | Alle Diskussionen |